NCT01590823View on ClinicalTrials.gov

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Blood Coagulation Disorders
Interventions
DRUG

Dabigatran Etexilate 110 mg

All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.

Trial Locations (1)

b3h 2y9

Capital Health District Authority, Department of Medicine, Division of Nephrology, Halifax

All Listed Sponsors
collaborator

Capital Health, Canada

OTHER

collaborator

Dalhousie University

OTHER

collaborator

Université de Montréal

OTHER

lead

Nova Scotia Health Authority

OTHER

NCT01590823 - An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients | Biotech Hunter | Biotech Hunter